Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note published on Thursday morning. The brokerage issued a sell rating on the stock.

MBRX has been the topic of several other reports. Maxim Group downgraded shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Moleculin Biotech in a report on Monday, March 3rd.

Moleculin Biotech Stock Down 2.6 %

MBRX stock opened at $1.13 on Thursday. The firm’s fifty day simple moving average is $1.42 and its 200-day simple moving average is $2.07. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $8.85.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.